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Abstract Amyloid  (A) immunoreactivity in neu-
rons was examined in brains of 32 control subjects, 31
people with Down syndrome, and 36 patients with spo-
radic Alzheimer’s disease to determine if intraneuronal
A immunoreactivity is an early manifestation of Alz-
heimer-type pathology leading to Wbrillar plaque for-
mation and/or neuroWbrillary degeneration. The
appearance of A immunoreactivity in neurons in
infants and stable neuron-type speciWc A immunore-
activity in a majority of brain structures during late
childhood, adulthood, and normal aging does not
support this hypothesis. The absence or detection of
only traces of reaction with antibodies against 4–13 aa
and 8–17 aa of A in neurons indicated that intraneu-
ronal A was mainly a product of - and -secretases
(A17–40/42). The presence of N-terminally truncated
A17–40 and A17–42 in the control brains was conWrmed
by Western blotting and the identity of A17–40 was
conWrmed by mass spectrometry. The prevalence of
products of - and  -secretases in neurons and - and
-secretases in plaques argues against major contribution
of A-immunopositive material detected in neuronal
soma to amyloid deposit in plaques. The strongest
intraneuronal A17–42 immunoreactivity was observed
in structures with low susceptibility to Wbrillar A
deposition, neuroWbrillary degeneration, and neuronal
loss compared to areas more vulnerable to Alzheimer-
type pathology. These observations indicate that the
intraneuronal A immunoreactivity detected in this
study is not a predictor of brain amyloidosis or
neuroWbrillary degeneration. The constant level of A
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390 Acta Neuropathol (2007) 113:389–402immunoreactivity in structures free from neuronal
pathology during essentially the entire life span sug-
gests that intraneuronal amino-terminally truncated
A represents a product of normal neuronal metabo-
lism.
Keywords Intraneuronal amyloid- · Plaques · 
Tangles · Down syndrome · Alzheimer’s disease
Introduction
NeuroWbrillary degeneration and brain amyloidosis
with deposition of Wbrillar amyloid  (A) in plaques
are diagnostic features of Alzheimer’s disease (AD).
Intracellular processing of amyloid precursor protein
(APP) with - and -secretases generates A1–40 and
A1–42 in the endoplasmic reticulum, trans-Golgi
network, and endosomal–lysosomal system [10, 19, 25,
62, 66]. An amino-terminally truncated 3-kd peptide
(A17–40/42) is the product of APP cleavage with - and
-secretase. Cells may produce and secrete several
species of A, including A1–40, A1–42/3 and A17–40/42
[8, 23, 24].
Human neurons are A-immunoreactive [11, 17, 22,
38, 39, 57]. The nature, distribution, and role of intran-
euronal A are the subject of controversy (see review
by Takahashi [58]). Intraneuronal A immunoreactiv-
ity has been localized in lipofuscin deposits [4, 65],
cathepsin D-positive vesicles of lysosomal origin [11],
multivesicular bodies within presynaptic and postsyn-
aptic compartments [57], and intracellular and extra-
cellular neuroWbrillary tangles (NFTs) [1, 21, 26, 27, 34,
42]. Several studies of cytoplasmic A immunoreactiv-
ity in neurons and glial cells in the human brain have
been conducted to determine the properties of A in
human neurons and its role in Wbrillar plaque forma-
tion [11, 17, 22, 39, 57]. The key observation has been
the absence of [64] or only minimal intraneuronal A
immunoreactivity [22] in normal brain. Therefore, the
appearance of or an increase in A immunoreactivity
has been suggested as a sign of neuronal pathology [22]
leading to Wbrillar plaque formation in the brain of
people with AD [11, 15, 22, 39, 63].
Overexpression of APP, overproduction of A, and
early intracellular accumulation of A [33] have been
considered the foundation for early onset of AD
pathology and functional deterioration in adults with
Down syndrome (DS) in their 40’s [22, 39, 63]. The loss
of A immunoreactivity in areas of plaque formation
has led to the conclusion that neurons release intracel-
lular A, which initiates a seeding process leading to
plaque formation [39]. According to Bahr et al. [2], the
death of neurons, a prominent feature of AD, is associ-
ated with the release of oligomerized intracellular A42
into the surrounding milieu, which may stimulate the
production of amyloidogenic fragments of APP,
amplify the levels of intracellular A in neighboring
cells, and act as a nidus for the deposition of secreted
A.
The association of intracellular A42 with intraneu-
ronal tangles has been considered an indication that
the growing concentration of A42 may contribute to
NFT formation [40]. The presence of altered aspartyl
residues in intracellular NFTs has been interpreted as
indicating that racemized A peptides are involved in
neuroWbrillary degeneration [41, 52].
The pattern of intraneuronal A immunoreactivity
observed in the control cohort in our previous study
[61] was in conXict with the hypothesis that A immu-
noreactivity in neurons is the key and an early event in
the cascade of pathology leading to AD. Therefore, the
aim of this study was to reexamine the hypothesis that
intraneuronal A immunoreactivity is an early mani-
festation of Alzheimer-type pathology leading to the
formation of Wbrillar plaque and/or neuroWbrillary
degeneration. To test this hypothesis, we examined
patterns of A accumulation in the human brain during
development, adulthood, and aging, and patterns of
changes in the amount and distribution of A in neu-
rons in people with DS and DS/AD, and sporadic AD.
Materials and methods
Human tissue
The brains of 99 individuals were examined. Control
brains included 32 cases, from 3 months to 102 years of
age (3-, 6-, 11-, and 13-month-old infants; 4-, 8-, 14-
year-old children; and adults from 23 to 102 years of
age; 19 males and 13 females). DS brains included 31
cases from 3 weeks to 72 years old (infants that were
3 weeks, and 3, 6, and 9 months old and adults from 28
to 72 years of age; 15 males and 16 females). In the AD
cohort, the brains of 36 subjects from 65 to 97 years of
age (17 males and 19 females) were studied. Diagnosti-
cally, three subjects had a mild cognitive impairment
(MCI) corresponding to global deterioration scale
(GDS) stage 3 [45, 46], a frequent clinical precursor of
AD. GDS stage 4 (mild AD) was reported for three
subjects; stage 5 (moderate AD) for three subjects;
stage 6 (moderately severe AD) for 11 subjects, and
stage 7 (severe AD) for 16 subjects.
One brain hemisphere was Wxed in 10% buVered
formalin for 1.5 to several months and then dissected123
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drated for 5 days in 70% ethanol, then 2 days in 80%
ethanol, and Wnally 1 week in 96% ethanol. The sam-
ples were inWltrated with polyethylene glycol (PEG)
400 (Merck #807,485) for 6 days (two changes of 3 days
each, at room temperature) and with PEG 1000 for
another 6 days (two changes of 3 days each, at 42°C).
The slabs were embedded in fresh PEG 1000 [28]. The
tissue blocks were cut serially at 50 m thick sections.
The immunoproperties of intracellular A in tissues
Wxed in formalin for 1.5 to several months were also
compared with immunostainings of sections from Wve
brains (two DS and three AD) preWxed in 4% parafor-
maldehyde for 2 h, dissected into 1 cm thick slabs, Wxed
in 4% paraformaldehyde for the next 24 h, cryopro-
tected with 15 and 30% solutions of sucrose (4 days),
frozen, and cut serially into 50 m thick sections.
The methods selected for this study were approved
by the New York State Institute for Basic Research
(IBR) Institutional Review Board. The tissue samples
were provided by the Silberstein Institute for Aging
and Dementia at New York University, the Brain
Bank at IBR, and the University of Miami Brain and
Tissue Bank. In postmortem examination, all samples
were identiWed only by an anonymous case number,
and tissue was examined blind to clinical and demo-
graphic information.
Immunostaining
Several antibodies were applied to serial sections to
evaluate A immunoreactivity in cortical and subcorti-
cal structures, the cerebellum, and brainstem. Mono-
clonal antibodies (mAbs) 6E10 and 6F/3D were used
for characterization of the amino-terminal portion of
A (Table 1). mAb 6E10 recognizes an epitope in resi-
dues 4–13 of A (Signet Laboratories, 1:10,000) [30, 36,
59]. mAb 6F/3D recognizes an epitope in residues 8–17
of A (Novocastra Laboratories Ltd; NCL--amyloid).
The central portion of A was detected with mAb 4G8,
which recognizes an epitope in residues 17–24 of A
[29]. The carboxyl terminus of A was characterized
with pAbs puriWed from rabbit serum by epitope-spe-
ciWc aYnity chromatography. These antibodies react
with A residues 32–40 (Catalog nr. 44–348) and 32–42
(Catalog nr. 44–344; BioSource International, Inc., CA,
USA). The reactivity towards other species of A pep-
tides was eliminated through a series of preabsorption
steps. PuriWed rabbit polyclonal antibodies, R164 and
165, speciWc for the carboxyl terminus of A1–42 (resi-
dues 35–42) were also used [37]. Fibrillar A was
detected with rabbit polyclonal antibody R262 pro-
duced by immunization of rabbits with Wbrillar A1–42.
Rabbit antibodies were puriWed according to the proto-
col described by Miller et al. [36].
Monoclonal antibody 6E10 reacts with A both on
western blots and in formalin Wxed material [13, 14].
mAb 6E10 binds APP on western blots, as a native
protein, but does not immunoreact with APP after Wxa-
tion with formalin and dehydration. We have also
shown that in cultures of cells overexpressing APP and
formalin Wxed and dehydrated both antibodies, 6E10
and 4G8 do not detect APP but they detect A [13].
Also, the study of cultured cells with elevated levels of
APP and C-terminal fragments of APP revealed that
mAb 4G8 does not detect APP and C-terminal frag-
ments of APP by immunocytochemistry [12] (Table 2).
The endogenous peroxidase in the sections was
blocked with 0.2% hydrogen peroxide in methanol. To
enhance immunoreactivity of A, sections were
treated with 90% formic acid for 30 min [31]. The sec-
tions were then treated with 10% fetal bovine serum in
phosphate buVer solution (PBS) for 30 min to block
nonspeciWc binding. The antibodies were diluted in
10% fetal bovine serum in PBS and were incubated
with sections overnight at 4°C. The sections were
washed and treated for 30 min with either biotinylated
sheep anti-mouse IgG antibody or biotinylated donkey
anti-rabbit IgG antibody diluted 1:200. The sections
were treated with an extravidin peroxidase conjugate
(1:200) for 1 h and the product of reaction was visual-
ized with diaminobenzidine (0.5 mg/ml with 1.5%
hydrogen peroxide in PBS). After immunostaining, the
sections were lightly counterstained with cresyl violet.
Table 1 Mouse monoclonal 
and rabbit polyclonal antibod-
ies used for immunocyto-
chemistry
Type Name Epitope Dilution Source
mAb 6E10 4–13 aa A 1:10,000 Signet Laboratories (developed at IBR)
mAb 6F/3D 8–17 aa A 1:50 Novocastra
mAb 4G8 17–24 aa A 1:8,000 IBR (Dr. R. Kascak)
pAb 44–348 32–40 aa A 1:500 Biosource
pAb 44–344 32–42 aa A 1:500 Biosource
pAb R164 35–42 aa A 1:500 IBR (Drs. D.L. Miller and P.D. Mehta)
pAb R165 35–42 aa A 1:500 IBR (Drs. D.L. Miller and P.D. Mehta)
pAb R262 Fibrillar A 1–42aa 1:200 IBR (Drs. D.L. Miller and P.D. Mehta)
mAb Tau1 189–207 aa of tau 1:100,000 IBR (Dr. R. Kascsak)123
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gles was detected with mAb Tau-1 (1:100,000). Tau-1
recognizes an epitope in residues 189–207 of the
human tau sequence [16]. To obtain optimum staining
with Tau-1, sections were treated with alkaline phos-
phatase (Sigma, Type VII-L, 400 g/ml in PBS, pH 7.4,
0.01% H2O2) [20].
A three-point classiWcation was used to estimate
semi-quantitatively the diVerence of immunoreactivity
with mAb 4G8 in four brain structures of 25 control
adult subjects. The amygdala and cornu Ammonis
were selected as structures susceptible to amyloidosis 
and neuroWbrillary degeneration. The lateral genicu-
late body and dentate nucleus were selected as struc-
tures resistant to AD pathology and almost free of
plaques and NFTs even in severe AD. Grade 1 corre-
sponded to weak immunoreactivity present in about
50% of neurons; grade 2 corresponded to moderate
immunoreactivity in almost all neurons; and grade 3
corresponded to strong immunoreactivity present in
almost all neurons in a given brain structure.
Sections from brain of DS subjects were used to
determine whether intraneuronal A immunoreactiv-
ity diVers in people with an extra copy of the gene
encoding APP. The diVerence between intraneuronal
A and amyloid in plaques was determined with anti-
bodies detecting the amino- and carboxyl-terminus and
the middle portion of A peptide. The relationship of
neuroWbrillary changes to A immunoreactivity in neu-
rons was evaluated in brains of people with DS/AD
and sporadic AD.
Partial puriWcation and identiWcation of A peptides
Samples of the brain cortex (250 mg) from control
males that were 31, 32 and 59 years-old were dispersed
in 2.5 ml of 99% formic acid by brief soniWcation and
centrifuged for 30 min at 100,000 g. Supernatants were
dried by centrifugal evaporation, the residues were
resuspended in 1 ml of 70% (v/v) formic acid and cen-
trifuged as above. The solutions were subjected to size-
fractionation on a 1 £ 30 cm Pharmacia HR-12 column
equilibrated with 70% formic acid as previously
described [36]. The A-containing fractions were identi-
Wed by Western blotting and their contents were quanti-
Wed by photodensitometry, as previously described [44].
The A-containing fractions were dried under vacuum
and were re-dried out of ammoniacal methanol to neu-
tralize traces of formic acid. To solubilize A peptides,
each residue was treated with 250 l of 50 mM ammonia
and centrifuged as above, and the supernatant liquid
was adjusted to pH 7.4 with KH2PO4.
Antibody R287, raised to A27–37 using the previ-
ously described methods [40] was puriWed on a peptide
aYnity column and was coupled to an Aminolink
matrix (Pierce-Endogen) at a concentration of
360 pmol per 200 l of settled matrix. The A isoforms
were immuno-adsorbed to 8 l of R287-agarose during
a 3 h incubation. Following washes with PBS and water
the A isoforms were eluted with 2 £ 100 l portions
of 2.5% triXuoroacetic acid in 50% acetonitrile. About
50% of total A peptides present in the cortex samples
were recovered by this method, as evaluated by West-
ern blotting. The shape and size of the A band in
Western blotting of the size-fractionated material and
the immuno-puriWed peptide were the same, which
suggested that the process did not selectively enrich
any of the A peptides.
Mass spectrometry and Western blotting
The peptide preparation isolated by immunoadsorption
on R287-agarose was dissolved in 30 l of 40% (v/v) for-
mic acid and approximately 82% was loaded on a Sym-
metry® C18 nanoAcquity column (180 m £  20 mm) as
six sequential 4.1 l injections. Following the sixth injec-
tion, the peptides were resolved on an Atlantis dC18
nanoAcquity column (100 m £  100 mm) with a
20 min gradient of 10 to 50% acetonitrile in water con-
taining 0.1% formic acid at Xow rate of 0.4 l/min. The
eluate from the column was analyzed directly on a Qtof
Micro (Waters Corp.) mass spectrometer equipped with
a nanoXow electrospayer and scanned for m/z 50–1,500
at 1.1 s intervals. An external lock mass standard (leu-
cine enkephalin; m/z =  556.2771) was analyzed at 11 s
intervals through a separate orthogonal electrosprayer.
The data were processed using MassLynx 4.0 (Waters
Corp.) software, including Accurate Mass Measure and
MaxEnt3 algorithms. BrieXy, chromatograms were cre-
ated from the data set by plotting a 1 Da window
Table 2 An¡40 and An¡42 concentration (pmol/g) in temporal
cortex
Brain samples were homogenized in formic acid as described in
Materials and methods. Aliquots of the extracts were neutralized
and subjected to PAGE and immunobloting. p4 bands migrated
above the 3 kDa standards and bound mAb 6E10. p3 bands mi-
grated near the 3 kDa standard and bound R162 or R226 but did
not bind mAb 6E10
a There was only one band in this extract. Its level was too low to
be revealed by mAb 6E10 and so could not be identiWed as p3 or p4
Control case # An¡40 An¡42 
p3 p4 p3 p4
247 2 2 1 0.3
256 2 1 2 1
1,169 0.3 0.3 0.2a 0.2a123
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to have the component of interest by summing the mass
spectra across the peak, determining the centroid m/z
values, followed by deconvolution and transformation
to the accurate mass value of the 1+ ion. The resulting
ion envelope encompassing mass isomers containing
zero to four 13C atoms was plotted to create the chro-
matogram of the speciWc peptide. For A17–40, the 2
+ ion
was by far the most prevalent and its ion envelope
spanned m/z values from 1196.3 through 1198.7. For
A1–40, the 4
+ and 5+ ions were the most prevalent, span-
ning m/z values from 1082.8 through 1084.8 and 866.4
through 868.0, respectively.
Western blotting was performed by a previously
described method, which allows the detection of sub-
femtomol quantities of A40 or A42 [44]. Samples and
appropriate standards were subjected to PAGE in tris-
tricine 16% gels. Rabbit polyclonal antibodies R162
(raised to A31–40) and R226 (raised to A32–42) were
used to detect the C-terminal sequences of A isoforms.
These antibodies are highly selective for their targets.
R162 showed no cross-reactivity with a 100-fold excess
of A42 [44], and R226 is 2500-fold more reactive with
A42 than with A40 [37]. Monoclonal antibody 6E10
[30] was used to detect the A sequence 4–13 [59]. The
blots were developed wth NBT and BCIP and the
bands were quantiWed by photodensitometry [44].
Results
Age-associated changes of A immunoreactivity 
in neurons in control and DS brains
Infants and children. In the majority of the brain struc-
tures examined, including the entorhinal cortex and
neocortex, amygdala, and hippocampus, A immuno-
reactivity was present in neurons of the 11 and 13
month-old normal infant brains and the 9 month-old
infant diagnosed with DS (Fig. 1). At this age, A-
immunoreactivity was observed in only about 5–10%
of the neurons. However, Wne and randomly dispersed
A-immunoreactive granules were present in the cyto-
plasm in almost all neurons in the dentate gyrus. In
infants, strong A-immunoreactivity was found in clus-
ters of cytoplasmic granules in almost all neurons in the
magnocellular portion of the lateral geniculate body,
but reaction in small neurons was rare and weak. In the
brains of 4 and 8 year-old children, about half of neu-
rons in the cortex and basal ganglia were A-immuno-
positive, whereas in the brain of the 14 year-old child,
the percentage of immunoreactive neurons was more
than 50%.
Adults. In adults, A immunoreactivity was present
in the majority of the neurons, but the amount and pat-
tern of distribution of immunopositive material showed
a broad range of cell-type- and brain structure-speciWc
diVerences. Strong A immunoreactivity characterized
all nuclei in the amygdala in adults, with the strongest
reaction in the lateral and ventral subdivisions (mean
grade, 2.3; SD § 0.4). In the amygdala, numerous A-
positive cytoplasmic granules were concentrated at one
pole of the cell and formed a perinuclear cap. In the
cornu Ammonis (CA), A immunoreactivity showed
marked sector-speciWc diVerences. Strong and uniform
reaction characterized neurons in the CA4 sector, and
moderate reaction was observed in CA2 and 3 sectors,
but A immunoreactivity in neurons in the CA1 sector
was much weaker and less uniform (mean grade in the
CA, 1.8; SD § 0.7). Apical dendrites in pyramidal neu-
rons in the CA and subiculum proper were often
marked with rows of A-immunoreactive granules.
Granule cells in the dentate gyrus contained numerous
randomly dispersed A-positive granules. Strong
immunoreactivity appeared in large neurons, and mod-
erate staining appeared in small neurons of the caudate
nucleus and putamen. Reactions in neurons in the thal-
amus, globus pallidus, and n. accumbens were less uni-
form and weaker. A immunoreactivity in cortical
pyramidal neurons was stronger and more common
than in cortical granule cells. In the cerebellum, a mod-
erate amount of Wne, granular A- immunoreactive
material was found in the majority of Purkinje cells, but
in granule cells, the reaction was weak and was present
only in a minority of cells. Very strong A immunore-
activity was found in the cytoplasm in all neurons in the
LGB and dentate nucleus (mean grade 2.8 § 0.4), as
well as in the nucleus olivaris.
Aged subjects. In general, in control people older
than 65 years of age, A immunoreactivity was
reduced in about 20% of neurons of the amygdala,
nucleus basalis of Meynert (NBM), cornu Ammonis,
large neurons in the caudate-putamen, and cortex, as
compared to control adults. However, the amount and
pattern of A immunoreactivity in the dentate gyrus,
LGB, dentate nucleus, and nucleus olivaris inferior
were comparable in aged subjects and normal adults.
In addition to the structure- and age-associated diVer-
ences in neuronal A immunoreactivity, there were
interindividual diVerences between people of the same
age and gender. Strong and uniform A immunoreactiv-
ity was found in 44% of the control subjects; moderate
and uniform in 40%, and weak and nonuniform in 16%.
No diVerence between control and DS infants (Fig. 1)
and adult with DS who has incipient neuroWbrillary
degeneration (28 years-old) was detected.123
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with neuroWbrillary degeneration and in DS/AD 
or sporadic AD
In the control group, mAb Tau-1 revealed neuroWbril-
lary degeneration in the brains of all persons older than
43 years of age. In the entorhinal cortex, subiculum,
and amygdala, the number of neurons with NFTs
increases with age. The increase in Tau-1-positive
material was paralleled by the reduction and loss of
cytoplasmic A immunoreactivity in aVected neurons
in the older subjects.
Fig. 1 Intraneuronal A immunoreactivity with mAb 4G8 (17–
24aa) in the CA1 sector, dentate gyrus (DG), amygdala (AMY),
lateral geniculate body (LGB), and cortex (COR; temporal supe-
rior gyrus) in 9 month-old infant with DS, 11 month-old control
infant, and 33 and 83 year-old control subjects (C) reveals age-
associated and structure-speciWc diVerences. A few immunoposi-
tive neurons are present in CA1 sector, amygdala, and cortex in
infants; however, immunopositivity is detectable in the majority
of neurons in infant dentate gyrus and lateral geniculate body. In
young adult (33 year-old) and aged subject (83 year-old) immu-
nopositivity is present in the majority of neurons and is much
stronger than in infants. Dense deposits are present in almost all
neurons in the LGB and amygdala, and dispersed Wne granular
staining is present in the majority of neurons in the dentate gyrus.
Loose granular immunopositive material appears in about 80%
of neurons in CA1 sector and cortical neurons123
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aVected with neuroWbrillary degeneration, and all peo-
ple with DS older than 38 years of age had developed 
amyloidosis. The increase in neuroWbrillary degenera-
tion, neuronal death, and  amyloidosis was associated
with marked reductions of intraneuronal A immuno-
reactivity in the entorhinal cortex (Fig. 2a, b), hippo-
campus, amygdala, NBM, and neocortex.
A similar pattern of reduction of A immunoreac-
tivity associated with neuroWbrillary degeneration,
amyloidosis , and neuronal loss was found in people
with MCI and subjects with sporadic AD (GDS stage
4–7). In severe AD (GDS stage 7), almost all neurons
in the second layer of the entorhinal cortex were
aVected by neuroWbrillary degeneration detected with
mAb Tau-1. These neurons contained only traces of
A immunoreactivity or were free of cytoplasmic A.
However, in neocortex, the reduction of intracellular
A immunoreactivity was less pronounced (Fig. 2c, d).
Both in persons with DS/AD and persons with spo-
radic AD, the percentage of A- immunopositive Pur-
kinje cells was reduced by about 25% compared to age-
matched control subjects. The majority of granule cells
failed to manifest A immunoreactivity. In the cerebel-
lum, the decrease in neuronal A immunoreactivity
was observed in the almost total absence of intraneuro-
nal NFTs.
In contrast to these patterns of reduction in A
immunoreactivity, a constant level of strong reaction
was present in almost all neurons in LGB, dentate
nucleus, and nucleus olivaris inferior in people with
DS/AD or sporadic AD. These structures were almost
Fig. 2 Development of neu-
roWbrillary tangles (arrow-
heads mAb Tau-1, a) in 
neurons in the second layer of 
the entorhinal cortex of a 
43 year-old subject with DS/
AD is associated with loss of 
cytoplasmic A immunoreac-
tivity (arrowheads mAb 4G8, 
b) without plaque formation 
in islands of stellate neurons. 
Amyloid plaque in the third 
layer (asterisk) is mAb 4G8-
positive. The insula of a sub-
ject with mild AD (GDS 4) is 
aVected by early and severe 
amyloidosis-. Plaques are 
marked with arrowheads (c). 
mAb 4G8-positive material is 
present in both plaques (aster-
isk) and neurons (arrowheads, 
d). The strongest A immuno-
reactivity is present in almost 
all neurons (arrowheads) in 
the lateral geniculate body 
(low and high magniWcation; 
AD, GDS 6; e), dentate nucle-
us (DS/AD, GDS 7; 72 year-
old; f), and nucleus olivaris 
inferior (DS/AD, GDS 7; 
72 years-old; g); however, 
amyloid plaques do not devel-
op in these structures, even in 
severe AD123
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including those with severe AD (Fig. 2e–g).
Immunoproperties of intraneuronal A
The lack of A immunoreactivity or presence of very few
cytoplasmic grains immunoreactive with antibodies
detecting an epitope in residues 4–13 (mAb 6E10) and
8–17 (mAb 6F/3D) and the presence of cytoplasmic
immunoreactivity with antibodies detecting 17–24 (mAb
4G8), 32–42 (pAb 44–344), and 35–42 (pAbs R164 and
165), indicates that neurons harbor mainly amino-termi-
nally truncated A (Fig. 3a, b, c, d, e, f). Stronger staining
of intracellular A with pAb 44–344 (residues 32–42)
and pAb R164 (35–42) than with pAb 44–348 (32–40),
indicates that the major component of cytoplasmic A in
neurons is A17–42. Intraneuronal A was not labeled
with pAb R262 that detects Wbrillar amyloid in cored
plaques and in vessel wall (not shown). The pattern of
immunostaining of A in Wbrillar plaques conWrmed that
parenchymal plaques contain mainly A1–42.
A immunoreactivity in ghost tangles
While neuronal neuroWbrillary changes were associ-
ated with loss of cytoplasmic A immunoreactivity,
some ghost tangles (extracellular NFTs) were A-posi-
tive (Fig. 3g, h, i). In the sporadic AD group, among 31
examined subjects, A-positive ghost tangles were
found in 24 brains (77%). The proportion of subjects
with A-reactive ghost tangles increased from 50% in
people with MCI to 70% in people with moderately
severe AD and to 100% in people with severe AD. A-
positive ghost tangles were found in 100% of these sub-
jects in the entorhinal cortex, in 87% in the CA1, 29%
in the amygdala, 21% in the CA2 and CA4, 8% in the
Fig. 3  a–f shows immunore-
activity of intraneuronal A in 
the CA4 sector of a 32 year-
old control subject. No reac-
tion in neurons stained with 
mAb 6E10 (4–13 aa) (a) and 
mAb 6F/3D (8–17 aa) (b) indi-
cates that in the majority of 
neurons, the amino-terminal 
portion of A is not detect-
able. Immunoreactivity of in-
traneuronal A is shown in 
sections stained with mAb 
4G8 (17–24 aa) (c), pAb R164 
(35–42 aa) (d), pAb 44–348 
(32–40 aa) (e) and pAb 44–
344 (32–42 aa) (f). In the brain 
of subjects with AD some 
extracellular ghost tangles 
contain full length A pep-
tides immunoreactive with 
antibodies 6E10 (g), 4G8 (h), 
and pAb 44–344 (i)123
Acta Neuropathol (2007) 113:389–402 397subiculum proper, and 4% in the CA3 and temporal
cortex. Of AD subjects with A-positive ghost tangles,
they were numerous in 41%, moderate in number in
17%, and were rare in 21% of the subjects.
In 13 of 24 brains of persons with DS (54%), A-
immunoreactive ghost tangles were found in the
entorhinal cortex, amygdala, and CA1 and CA2 sectors.
The youngest subject with positive staining was 43 years
of age at demise. A-positive ghost tangles were found
in the brains of all DS subjects from 55 to 72 years old.
Of DS subjects in whom A-immunoreactive ghost tan-
gles were present, they were numerous in 46%, moder-
ate in number in 39%, and rare in 15% of subjects.
In the control cases, no A-immunoreactive ghost
tangles were observed in spite of the presence of neu-
roWbrillary changes in all subjects older than 43 years
of age.
A-positive ghost tangles were strongly immunoreac-
tive with mAbs 6E10 (residues 4–13), 6F/3D (8–17), and
4G8 (17–24), and pAbs 44–344 (32–42) and R165 (35–
42). The reaction with pAb 44–348 (32–40) was weak.
A isoforms could be detected on Western blots 
of crude control brain extracts
Antibody R162 revealed 2 bands containing the A32–40
sequence (Fig. 4, lane 3), whereas antibody R226
revealed 2 bands containing the A33–42 C-terminal
sequence (Fig. 4, lane 4). Immunoreactivity with mAb
6E10 (Fig. 4, lane 5) unequivocally showed that the
upper band contained A peptide sequences possessing
amino acid residues 4–13. This antibody does not bind
to A17–40 even at a 15-fold higher concentration (Fig. 4,
lane 6). We found that the large amounts of other pro-
teins in the extracts aVected the electrophoretic migra-
tion rates and band shapes of the peptides, so that their
migration rates did not unambiguously distinguish
A1–40 from A17–40. Using synthetic A standards we
showed that substances in a crude brain extract
retarded the migration of A17–40 so that it migrated at
the rate of A1–40 (in the absence of brain extract).
Peptides with a deWned C-terminus may have distinct
N-termini, hence, we operationally deWne the p4 pep-
tides as those that bind mAb 6E10 and migrate between
the 3 and 6 kDa standards. Monoclonal antibody 6E10
binds to A residues 4–13; therefore, p4 may contain
peptides whose N-terminal residues are Asp1–Arg5. We
deWne the p3 peptides as those that migrate near the
3 kDa standard and do not bind 6E10. The levels of
A40 peptides in three normal brain cortex samples
were between 0.3 and 2 pmol/g of p3 and between 0.3
and 3 pmol/g, and the levels of A42 peptides were
between 0.2 and 2 pmol/g of p3 and between 0.2 and
1 pmol/g. Although these amounts are readily detect-
able, they are 3–4 orders of magnitude below the A lev-
els in an AD brain sample that we analyzed (not shown).
Detection of A17–40 by mass spectrometry
We immunoprecipitated 650 fmol of A peptides from
brain C247 and characterized both the chromatographic
behavior and the masses of the peptides by mass spec-
trometry using the coupled capillary HPLC-MS system.
As shown in Fig. 5, the identity of the A peptide A17–
40 from the brain was conWrmed by comparison to syn-
thetic A17–40, which eluted at the same time and dis-
played the same m/z proWle. Deconvolution and
transformation of the A17–40 2
+ ion spectrum to the 1+
monoisotopic mass gave mass values of 2392.2852 Da
(brain sample) and 2392.2813 Da (synthetic) compared
to the theoretical value of 2392.2950 Da (4.1 ppm and
5.7 ppm errors, respectively). We also observed ion pro-
Wles consistent with A1–40 4
+ and 5+ ions in the mass
spectra. The presence of detergent in the sample and
the complexity of the chromatogram and spectra com-
plicated the identiWcation of other A species.
Discussion
A immunoreactivity in neurons in normal brain
Previous studies either did not Wnd intracellular A
immunoreactivity in brains of control subjects [64] or
Fig. 4 A isoforms in extracts from control brain 247 revealed by
immunoblotting. A formic acid extract of cerebral cortex from
brain C247 was prepared as described in the methods section. A
portion of the dried extract was dissolved in PAGE sample buVer
and a 15 l aliquot containing 30 g of protein (equivalent to
300 g of tissue) was applied to the lanes developed with R162
and R226. Because mAb 6E10 is much less sensitive than R162 or
R226, the formic acid extract was fractionated by size-exclusion
as described in the methods section. The fraction containing pep-
tides in the mass range 2,000–12,000 Da was concentrated, and an
aliquot containing peptides from 12 mg of tissue was applied to
the lane developed with 6E10. The extracts were subjected to
PAGE and blotting along with synthetic A standards and molec-
ular mass markers as described in the text. The blots were devel-
oped with antibody R162 (to the C-terminus of A32–40), R226 (to
the C-terminus of Abeta33–42) or mAb 6E10 (to A4–13). Lane 1
2 fmol A1–40, lane 2 2 fmol A17–40, lane 6 150 fmol A17–40, lane
7 10 fmol A1–40. Molecular mass markers denoted on the right-
hand margin are insulin single chains and aprotinin123
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ity (15%) of examined adults [22]. Therefore, it was
proposed that the accumulation of intraneuronal A is
involved in early AD pathology [17]. However, this
study of control cases, from several months to
102 years of age demonstrates that intraneuronal A
immunoreactivity appears in the Wrst year of life,
increases in childhood, stabilizes in the second decade
of life, and remains high throughout adulthood. Detec-
tion of stable intracellular A immunoreactivity in
neurons in control cases throughout the entire life may
indicate that A-immunoreactive material in the cell
body reXects normal neuronal metabolism and is not
neuronal pathology.
The observation that intraneuronal A in control,
DS/AD, and sporadic AD cases was almost exclusively
amino-terminally truncated conWrmed and extended
the Wndings of the Mori et al. [39] study of people with
DS and the Sergeant et al. [51] study showing that
amino-truncated A peptides represent more than
60% of all A species in subjects with preclinical AD.
A peptides with N-terminal deletions exhibit
enhanced peptide aggregation relative to full-length
species [43] and retain the neurotoxicity and -sheet
structure. It was hypothesized that A17–42 peptides
may initiate and/or accelerate plaque formation, per-
haps by acting as nucleating centers that seed the sub-
sequent deposition of relatively less amyloidogenic but
apparently more abundant full-length A [18, 43, 48].
Gouras et al. [17] considered intracellular A42 accu-
mulation to be an early event leading to neuronal dys-
function. However, the appearance of intraneuronal
A immunoreactivity in the Wrst year of life, and the
stable and strong immunoreactivity throughout adult-
hood, in the absence of morphological signs of cell
injury or degeneration, suggests that A detected in
neurons with applied antibodies does not adversely
aVect cell structure. This lack of Wbrillization and toxic-
ity may indicate that these A species remain in inert
form. Possibly this inert state is maintained by binding
with blockers of Wbrillization and toxicity. The trans-
port of A within cytoplasmic vesicles or vacuoles [57]
might be another factor preventing the expression of
their cytotoxic activity. The detected intraneuronal
Fig. 5 Chromatographic elution proWle of A17–40. Samples from
(a) control brain C247 and (b) synthetic A17–40 were prepared
and analyzed by LC-MS as described in “Materials and methods”.
The chromatograms show only the MS ion counts for the M+2H+
ions of A17–40 mass isomers containing zero to four 
13C atoms (m/
z = 1196.3–1198.7). The ion intensities determined at 1.1 s inter-
vals were summed, background subtracted and smoothed. The y-
axis scale is 400 ions per second full scale (100%). The identiWca-
tion of A17–40 in the peaks at 24.4 (a) and 24.5 (b) minutes was
demonstrated by the characteristic ion envelope obtained from
the centroid accurate mass spectra for the A17–40 M+2H
+ ions
from each peak (24.2 to 24.7 min) shown in the insets 123
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unknown function. Higher levels of secreted APP and
nonamyloidogenic secreted APP and lower levels of
A 40 in children with severely autistic behavior and
aggression compared with controls [54] may indicate
that modiWcations of APP processing and potentially
A traYcking are clinically signiWcant in absence of
neurodegeneration or neuronal loss.
The very strong A immunoreactivity in the LGB,
nucleus olivaris inferior, and dentate nucleus during
the entire course of human adulthood and the absence
of or minimal amyloid load in very severe AD oppose
the hypothesis that strong intraneuronal A immuno-
reactivity is a predictor of Wbrillar plaque formation.
Convergent Wndings in PS1 tg mice have been reported
by Chui et al. [9].
This study suggests also that the intensity of intran-
euronal A immunoreactivity is not a predictor of
neuroWbrillary degeneration. The strongest A immu-
noreactivity was observed in neurons in the LGB,
nucleus olivaris inferior, and dentate nucleus, which
remain free of neuroWbrillary degeneration in very
severe AD. The moderate A immunoreactivity in the
second layer of the entorhinal cortex and pyramidal
neurons in the CA1, observed in this study, and the
early onset of NFTs observed in these neuronal popu-
lations [5–7] also question the link between A immu-
noreactivity and susceptibility to neuroWbrillary
degeneration.
The lack of pathological changes in brain structures
with the strongest intraneuronal A immunoreactivity
during the entire human lifespan may indicate that
amino-terminally truncated A is a product of cell
metabolism that does not (1) limit cell survival, (2) pre-
dispose to Wbrillar A deposition in plaques, nor (3)
cause neuroWbrillary degeneration.
Reduction of intraneuronal A immunoreactivity
in DS/AD and sporadic AD
In this study, the strongest intraneuronal A immuno-
reactivity was found in control cases, compared to
those with AD and in DS/AD. SigniWcant weaker A
immunoreactivity in neurons in people with DS/AD
and sporadic AD appear to be the result of AD pathol-
ogy, including neuroWbrillary degeneration and neuro-
nal loss.
In the memory systems of persons with DS/AD or
sporadic AD, neuroWbrillary degeneration is the major
cause of neuronal loss and, therefore, the major factor
contributing to the reduction of intraneuronal A.
Over the course of 22 years, an AD patient loses 87%
of the neurons in the CA1 and 63% in the CA4 sector,
and 77% in the subiculum [5]. People with DS/AD
older than 50 years of age are aVected by severe loss of
neurons including 98% loss in the second layer of the
entorhinal cortex, 74% in the CA1 sector, 57% in the
subiculum proper, and 71% in the amygdala [32, 60].
Large portions of surviving neurons in the brains of
people with AD and DS/AD are aVected with neuroW-
brillary changes, yet they show little or no A immuno-
reactivity. These changes explain, in part, the loss of
A immunoreactivity in neurons in the plaque perime-
ter, as noted in persons with DS/AD [39]. The lower
intraneuronal A immunoreactivity observed in peo-
ple with sporadic AD or DS/AD may also reXect a shift
in APP processing. This shift would be from amino-ter-
minally truncated A accumulation in cell cytoplasm in
normal brain to APP processing with enhanced genera-
tion and secretion of A1–40/42 in people with AD.
Accumulation of A1–40/42 in ghost tangles
Intracellular and extracellular NFTs have been shown
to be A immunoreactive [1, 21, 27, 34, 42, 49, 56].
However, studies of puriWed PHF revealed the absence
of beta-pleated sheet conformation or any other char-
acteristic of an amyloid [50]. It was proposed that the
staining of intraneuronal PHF with antibodies to amy-
loid is due to the proximity of A molecules to the
PHF in the cytoplasm of neurons [47]. Deposition of
A within extracellular NFTs has been considered a
secondary event [67].
Strong immunoreactivity of extracellular NFTs with
antibodies 6E10 (residues 4–13), 6F/3D (8–17), 4G8
(17–24), 44–344 (32–42) and R165 (35–42) could be an
indicator of the presence of full length of A in extra-
cellular space. The weak reaction of ghost tangles with
pAb 44–348 (32–40) may suggest a lower concentration
of this form of A in the extracellular space. An
increase in the percentage of A-positive ghost tangles
in people with progressing AD appears to reXect the
increase in the percentage of neurons dying due to neu-
roWbrillary degeneration and an increasing concentra-
tion of full length A in the extracellular space. Spatial
and temporal separation of plaques and A-positive
ghost tangles indicates that ghost tangles may bind A,
but do not initiate Wbrillar plaque formation.
Interindividual diVerences in intraneuronal 
A immunoreactivity
Intraneuronal A immunoreactivity revealed some
interindividual diVerences. Gouras et al. [17] observed
increased apo-E immunoreactivity in A42-immunore-
active neurons and suggested that apo E might be a123
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Neuron-generated apo-E may bind to neuronal A and
aVect both its secretory pathway and its storage in the
cell cytoplasm. The lack of apo-E in the oVspring of
APP tg mice crossed with apo-E knockouts reduces
signiWcantly the amyloid load [3]. Chronic inXamma-
tion is another factor that may inXuence amyloid for-
mation [53].
In the human brain, there appear to be several pools
of A in equilibrium [35]. In this study, we demon-
strate by the immunocytochemical method abundant
intraneuronal amino-terminally truncated A17–40/42
with minor presence of the intraneuronal A1–40/42. The
presence of the A17–40 peptide in control cortex sam-
ples was conWrmed by mass spectrometry. However, in
extracts from cerebral cortex we identiWed by Western
blotting the A40 peptides that were amino-terminally
truncated (A17–40) and full length A1–40 in similar
quantities. We also detected both the A17–42 peptide
and the full length A1–42 peptide, although the levels
of the latter were 2 or 3 times lower than those of
the amino-terminally truncated one. The diVerences
between the A peptides detected in the brain by the
immunocytochemical and biochemical methods sug-
gest that the A peptides accumulated intraneuronally
are mainly those amino-terminally truncated, while the
full length peptides are mainly dispersed in extracel-
lular space, and hence are not detected by the immu-
nocytochemical method as intracellular deposits.
Deposition of full length A in ghost tangles and the
increase of A-positive ghost tangles could be consid-
ered an indicator of the presence of A1–42 in extracel-
lular space and an increase of this extracellular form of
A in advanced stages of AD.
It appears that the immunocytochemical methods
applied in this and other studies [11–14, 17, 22, 39] do
not monitor the neuronal secretory pathway of APP
processing leading to normal secretion of A1–40 and
A1–42. Stern et al. [55] have shown that full length
APP is extremely sensitive to Wxation methods and its
immunogenicity could be easily destroyed. The possi-
bly enhanced secretion of these peptides in AD that
may result in Wbrillar A deposition in plaques also is
not detected. The lack of detection or poor detectabil-
ity of the product of - and -secretases in autopsy
material might be the result of tissue preservation
method, the minute amount of A1–40/42 that might be
secreted without long-term storage, the prevalence of
amino-terminally truncated A masking the detection
of A1–40/42, or the masking of the amino-terminal
epitopes by interactions with other proteins. One
may speculate that deposition of amino-terminally
truncated A might be up- or down-regulated by
physiological and pathological factors independently
of any changes in the secretory pathway.
This study suggests that neuron-type- and brain-
structure-speciWc patterns of intraneuronal A immu-
noreactivity, established in teenagers and maintained at
a constant level during adulthood and aging, reXect nor-
mal cell metabolism rather than pathological changes.
Reduction and loss of immunoreactivity in neurons with
neuroWbrillary changes appears to be a response to the
progression of pathological changes in the neuron. The
absence of a link between the age at onset and the pro-
gression of accumulation of intraneuronal A-positive
material in control subjects with the Wbrillar plaque for-
mation or neuroWbrillary degeneration in people with
AD indicates that the form of intraneuronal A,
detected by applied methods, does not predict plaque
formation or neuroWbrillary degeneration.
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